Genomic data on GIST also show that mutations in other key signaling proteins, such as KRAS, BRAF, PIK3CA, PTEN could also mediate resistance to KIT/PDGFRA inhibitors [23–25]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.